Open Access<p>Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR)</p>
Author(s) -
Gurjyot K. Doshi,
Abhijeet Bhanegaonkar,
Mairead Kearney,
Murtuza Bharmal,
Paul Cislo,
Ruth Kim,
Marley Boyd,
Kathleen M. Aguilar,
Hemant Phatak
Publication year - 2020
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s264942
Subject(s) - medicine , bladder cancer , regimen , oncology , chemotherapy , cancer , urothelial cancer , subgroup analysis , meta analysis
Clinical trial evidence has affirmed the role for immuno-oncology (IO) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC). This Study informing treatment Pathway dEcision in bladder cAnceR (SPEAR-Bladder) aimed to provide insight into the optimal sequencing of IO treatments among la/mUC patients treated in the US Oncology Network.